P35 as a drug target in cancer therapy

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 6, 2001, Pages 923-935

  Chene P ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antisence oligonucleotide; Cancer; Gene therapy; Immunotherapy; Mdm2; P53

Indexed keywords

1 ETHYL 2 [[3 ETHYL 5 (3 METHYLBENZOTHIAZOLIN 2 YLIDENE) 4 OXOTHIAZOLIDIN 2 YLIDENE]METHYL]PYRIDINIUM CHLORIDE; 10 HYDROXYCAMPTOTHECIN; 4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; DNA; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; LIPOSOME; ONYX 015; PACLITAXEL; PIPERAZINE DERIVATIVE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; TOPOTECAN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER IMMUNOTHERAPY; CANCER SUSCEPTIBILITY; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG STRUCTURE; DRUG TARGETING; GENE THERAPY; GENE TRANSFER; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PATENT; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW; TUMOR CELL; TUMOR SUPPRESSOR GENE;

EID: 0034975161     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.6.923     Document Type: Review

References (123)

1. p53, the cellular gatekeeper for growth and division
2. The p53 tumour suppressor gene
3. Mechanisms of p53-mediated apoptosis
4. Introduction: P53-the first twenty years
5. p53 and human cancer: The first ten thousand mutations
6. p53: Puzzle and paradigm
7. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
8. New approaches to understanding p53 gene tumor mutation spectra
9. p53 website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis
10. p53 mutations in human cancers
11. Roles for p53 in growth arrest and apoptosis: Putting on the brakes after genotoxic stress
12. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
13. p53 tumor suppressor gene therapy for cancer
14. The current status of gene therapy
15. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
16. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers
17. p53 tumor suppressor gene therapy for cancer
18. p53-oriented cancer therapies: Current progress
19. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck,. Ovarian, prostate and breast cancer
20. Strategies for enhancing viral-based gene therapy using ionizing radiation
21. Does p53 status influence tumor response to anticancer therapies?
22. p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy
23. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation
24. Enhanced radiosensitivity of malignant glioma cells after adenoviral p53 transduction
25. Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy
26. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene
27. Modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin
28. Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models
29. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate and breast cancer
30. Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells
31. Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene
32. Synergistic chemosensitization and inhibition of tumor growth and metastasis by adenovirus-mediated P53 gene transfer in human bladder cancer model
33. Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer
34. Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer
35. Ligand-directed retroviral targeting of human breast cancer cells
36. Targeting DNA to cells with basic fibroblast growth factor (FGF2)
37. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors
38. Liposomes as vehicles for targeted therapy of cancer. Part 1: Preclinical development
39. Liposomes as vehicles for targeted therapy of cancer. Part 2: Clinical development
40. Lipoplexes and tumours. A review
41. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice
42. Intracavitary liposome-mediated p53 gene transfer into glioblastoma with endogenous wild-type p53 in vivo results in tumor suppression and long-term survival
43. Heterogeneous induction of apoptosis in colon cancer cells by wild-type p53 gene transfection
44. Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes
45. Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro
46. Transferrin as a targeting ligand for liposomes and anticancer drugs
47. Targeted drug delivery via the folate receptor
48. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
49. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
50. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy
51. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A Phase II trial
52. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
53. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients
54. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: Dependence on sequencing but not p53 functional status or route of administration
55. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy
56. Adenovirus-mediated cytotoxicity of chronic lymphocytic leukemia cells
57. Regulation of the specific DNA binding function of p53
58. Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants
59. Regulation of the cryptic sequence-specific DNA-binding function of p53 by protein kinases
60. Allosteric activation of latent p53 tetramers
61. Reactivation of mutant p53: A new strategy for cancer therapy
62. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus
63. Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments
64. Activation of the cryptic DNA binding function of mutant forms of p53
65. Flexibility: The key to p53 function?
66. Thermodynamic stability of wild-type and mutant p53 core domain
67. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: Definition of mutant states for rescue in cancer therapy
68. Small peptides activate the latent sequence-specific DNA binding function of p53
69. Restoration of the transcription activation function to mutant p53 in human cancer cells
70. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain
71. Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain
72. Modification of two distinct COOH-terminal domains is required for murine p53 activation by bacterial Hsp70
73. Pharmacological rescue of mutant p53 conformation and function
74. Principles of protein folding in the cellular environment
75. Geldanamycin selectively destabilizes and conformationally alters mutated p53
76. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90
77. Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo
78. Mdm2: The ups and downs
79. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
80. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase
81. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53
82. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein
83. The MDM2 gene amplification database
84. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage
85. Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression
86. A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer
87. Enhancement of drug-induced apoptosis by antisense oligodeoxynucleotides targeted against Mdm2 and p21WAF1/CIP1
88. MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis
89. MDM2 oncogene as a target for cancer therapy: An antisense approach
90. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain
91. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53
92. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines
93. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53
94. The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2
95. Cytoplasmic sequestration of wild-type p53 impairs the G1 checkpoint after DNA damage
96. Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member
97. NIH 3T3 cells malignantly transformed by mot-2 show inactivation and cytoplasmic sequestration of the p53 protein
98. Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function
99. p53 Antibodies in the sera of patients with various types of cancer: A review
100. p53 as a target for anti-cancer immunotherapy
101. p53-based immunotherapy of cancer
102. Idiotypic immunization induces immunity to mutated p53 and tumor rejection
103. Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides
104. Mutant oncopeptide immunization induces CTL specifically lysing tumor cells endogenously expressing the corresponding intact mutant p53
105. Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif
106. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes
107. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas
108. p53: A potential target antigen for immunotherapy of cancer
109. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: Implications for immunoselection of epitope loss variants
110. p53 as a target for cancer vaccines: Recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge
111. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy
112. Redox regulation of p53 during hypoxia
113. Identification of redox/repair protein Ref-1 as a potent activator of p53
114. Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo
115. Thioredoxin-dependent redox regulation of p53-mediated p21 Activation
116. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro
117. Antioxidant action via p53-mediated apoptosis
118. Pyrrolidine dithiocarbamate prevents p53 activation and promotes p53 cysteine residue oxidation
119. Induction of apoptosis by thiuramdisulfides, the reactive metabolites of dithiocarbamates, through coordinative modulation of NFκB, c-fos/c-jun and p53 proteins
120. Mdm2 promotes the rapid degradation of p53
121. Regulation of p53 stability by Mdm2
122. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520(ONYX-015)
123. New insights into p53 regulation and gene therapy for cancer